Skip to content

A prospective trial to compare the usefulness of NBI versus iodine staining during esophageal squamous carcinoma ESD

A prospective trial to compare the usefulness of Narrow Band Imaging versus iodine staining during esophageal squamous carcinoma Endoscopic Submcosal Dissection - DISCOVER trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1052240113
Enrollment
400
Registered
2024-08-22
Start date
2024-08-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal squamous carcinoma Narrow Band Imaging, iodine staining, esophageal squamous carcinoma, Endoscopic Submucosal Dissection

Interventions

<Period From the date of publication of the jrct to December 31, 2026 <Targets Patients scheduled for endoscopic submucosal dissection (ESD) for superficial esophageal cancer. <Allocation Patients wil
randomized enrollment and assigned to two groups

Sponsors

Fukunaga Shusei
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following selection criteria and do not meet any of the exclusion criteria will be included in this study. Patients with superficial esophageal cancer 1. patients scheduled to undergo ESD between the jRCT publication date and December 2026 2. patients who are able to undergo endoscopic observation 2-3 months after the date of publication of the jRCT 3. Patients who are at least 20 years of age at the time of the first ESD treatment

Exclusion criteria

Exclusion criteria: 1. Patients with superficial esophageal cancer of the entire circumference 2. patients who have been previously enrolled in this study 3. pregnant, possibly pregnant, or lactating 4. patients with psychosis or psychiatric symptoms that would make it difficult for them to participate in the study 5. patients with iodine allergy 5. patients who are allergic to iodine and have difficulty with iodine spraying 6. patients scheduled to be treated for advanced cancer of other organs within 3 months 7. patients with a lesion in close proximity to the study site 8. other patients who are deemed inappropriate for the study by the treating physician

Design outcomes

Primary

MeasureTime frame
Percentage of correct diagnosis of tumor extent

Secondary

MeasureTime frame
Aspiration pneumonia rate, marking time, treatment time, and post-resection ulcer base circumference, area of resection specimen, percentage of positive horizontal margins, percentage of post-ESD stenosis, percentage of cancer remnant at ESD ulcer healing (2-3 months later), risk factors for misdiagnosis

Contacts

Public ContactMitsuhiro Kono

Osaka Metropolitan University Hospital

bokuri.1229@omu.ac.jp+81-6-6645-2316

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026